OVARIAN MUCINOUS CYSTADENOCARCINOMA
Clinical trials for OVARIAN MUCINOUS CYSTADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN MUCINOUS CYSTADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN MUCINOUS CYSTADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for rare ovarian cancer: which chemo combo works best?
Disease control OngoingThis phase 3 trial tests two different chemotherapy regimens, with or without the targeted drug bevacizumab, as first treatment for a rare type of ovarian or fallopian tube cancer called mucinous epithelial cancer. About 50 patients with newly diagnosed or recurrent cancer will b…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC